These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 17119025)

  • 1. American Society of Preventive Oncology Distinguished Career Achievement Lecture 2006--Enjoy the journey: the long and winding road of chemoprevention agent development.
    Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2038-41. PubMed ID: 17119025
    [No Abstract]   [Full Text] [Related]  

  • 2. Food extracts for chemoprevention: quo vadis?
    Meyskens FL
    Cancer Prev Res (Phila); 2009 Jul; 2(7):608-10. PubMed ID: 19584073
    [No Abstract]   [Full Text] [Related]  

  • 3. [N. N. Petrov Research Institute of Oncology: present and future].
    Beliaev AM
    Vopr Onkol; 2012; 58(2):140-7. PubMed ID: 22774516
    [No Abstract]   [Full Text] [Related]  

  • 4. The next phase of chemoprevention research.
    Cohen EE; Schilsky RL
    Cancer Prev Res (Phila); 2011 Mar; 4(3):293-5. PubMed ID: 21372026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin chemoprevention: the long road to clinical translation.
    Shureiqi I; Baron JA
    Cancer Prev Res (Phila); 2011 Mar; 4(3):296-8. PubMed ID: 21372027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical development plan: vitamin A.
    J Cell Biochem Suppl; 1996; 26():269-307. PubMed ID: 9154183
    [No Abstract]   [Full Text] [Related]  

  • 7. Cancer clinical trials: the emergence and development of a new style of practice.
    Keating P; Cambrosio A
    Bull Hist Med; 2007; 81(1):197-223. PubMed ID: 17369668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development plan: sulindac sulfone.
    J Cell Biochem Suppl; 1996; 26():227-35. PubMed ID: 9154180
    [No Abstract]   [Full Text] [Related]  

  • 9. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
    Armstrong WB; Taylor TH; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
    [No Abstract]   [Full Text] [Related]  

  • 10. Ontology, oncology, and preventive economies: developing drugs for cancer prevention.
    Vogel VG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5227-8. PubMed ID: 17875747
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?
    Hidalgo M
    Adv Exp Med Biol; 2008; 610():128-43. PubMed ID: 18593020
    [No Abstract]   [Full Text] [Related]  

  • 12. Chemoprevention clinical trials: it is time to turn success into progress.
    Brown PH
    Cancer Epidemiol Biomarkers Prev; 2007 Aug; 16(8):1531-2. PubMed ID: 17684123
    [No Abstract]   [Full Text] [Related]  

  • 13. Ligand-based vascular targeting of disease.
    Rybak JN; Trachsel E; Scheuermann J; Neri D
    ChemMedChem; 2007 Jan; 2(1):22-40. PubMed ID: 17154429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
    Herberman RB; Pearce HL; Lippman SM; Pyenson BS; Alberts DS
    Cancer Res; 2006 Dec; 66(24):11540-9. PubMed ID: 17158189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development plan: l-Selenomethionine.
    J Cell Biochem Suppl; 1996; 26():202-18. PubMed ID: 9154178
    [No Abstract]   [Full Text] [Related]  

  • 16. 25 years of oncology.
    Spittle MF
    Br J Hosp Med; 1991 Oct; 46(4):249, 251. PubMed ID: 1954491
    [No Abstract]   [Full Text] [Related]  

  • 17. C-Path: updating the art of pathology.
    Martin M
    J Natl Cancer Inst; 2012 Aug; 104(16):1202-4. PubMed ID: 22899628
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
    Park JW; Kerbel RS; Kelloff GJ; Barrett JC; Chabner BA; Parkinson DR; Peck J; Ruddon RW; Sigman CC; Slamon DJ
    Clin Cancer Res; 2004 Jun; 10(11):3885-96. PubMed ID: 15173098
    [No Abstract]   [Full Text] [Related]  

  • 19. [Thirty four years of reports from the war against cancer].
    Thomsen ML
    Ugeskr Laeger; 2005 Dec; 167(50):4746-7. PubMed ID: 16393535
    [No Abstract]   [Full Text] [Related]  

  • 20. Where does hematology end and oncology begin? Questions of professional boundaries and medical authority.
    Krueger G; Canellos G
    J Clin Oncol; 2006 Jun; 24(16):2583-8. PubMed ID: 16735712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.